N.B., for each set of comparisons, demographics were compared, and significant differences that affected a particular outcome were addressed via the respective statistical models.
Supplemental Methods
The CIBMTR (Center for International Blood and Marrow Transplantation Registry) is a voluntary research organization involving more than 500 transplantation centers collaborating to share patient data and conduct scientific studies. Data management manuals provide instructions on data submission. Quality and compliance are monitored by computerized checks for errors, physician reviews, on-site audits, and annual training.
Patient-and transplant-related variables included recipient age; gender; race; Karnofsky performance score (KPS) at HSCT; graft source (BM or PBSC); donor type (HLA-matched sibling donor vs well-matched URD vs partially matched URD); degree of HLA-matching; donor/ recipient sex match; CMV serology, and ABO status; conditioning regimen (total body irradiation (TBI)-containing versus non-TBI); aGvHD prophylaxis regimen (stratified by use of steroids or MMF); development of cGvHD; and year and center of transplant. Disease-related variables included diagnosis, disease status at transplantation (early, intermediate, or Year of HSCT 0.0001 <0.0001 a Stratification for multivariable analysis for Overall Survival (MRD): for year of HSCT -2000 HSCT - -2004 HSCT - , 2005 HSCT - -2008 HSCT - , and 2009 HSCT - -2012  for disease type -AML, MDS, CML and ALL; for disease stage -early, intermediate, advanced and unknown. b Stratification for multivariable analysis for Overall Survival (MUD): for year of HSCT -2000 HSCT - -2004 HSCT - , 2005 HSCT - -2008 HSCT - , and 2009 HSCT - -2012  for graft source -bone marrow and peripheral blood; for Karnofsky group status (KPS) -<90% or > 90% at HSCT. c Stratification for multivariable analysis for Disease-Free Survival (MRD): for disease type -AML, MDS, CML and ALL; for graft source -bone marrow and peripheral blood. d Stratification for multivariable analysis for Disease-Free Survival (MUD): for year of HSCT -2000 HSCT - -2004 HSCT - , 2005 HSCT - -2008 HSCT - , and 2009 HSCT - -2012  for graft source -bone marrow and peripheral blood; for disease type -AML, MDS, CML and ALL; for KPS -<90% or > 90% at HSCT. e Stratification for multivariable analysis for Relapse (MRD): for disease type -AML, MDS, CML and ALL; for graft sourcebone marrow and peripheral blood. f Stratification for multivariable analysis for Relapse (MUD): for year of HSCT -2000 HSCT - -2004 HSCT - , 2005 HSCT - -2008 HSCT - , and 2009 HSCT - -2012  for graft source -bone marrow and peripheral blood; for disease type -AML, MDS, CML and ALL. g Stratification for multivariable analysis for TRM (MRD): for year of HSCT -2000 HSCT - -2004 HSCT - , 2005 HSCT - -2008 HSCT - , and 2009 HSCT - -2012  for sex match -M/M, M/F, F/M, F/F based on donor/recipient sex. h Stratification for multivariable analysis for TRM (MUD): for year of HSCT -2000 HSCT - -2004 HSCT - , 2005 HSCT - -2008 HSCT - , and 2009 HSCT - -2012  for graft source -bone marrow and peripheral blood; for disease type -AML, MDS, CML and ALL; for sex match -M/M, M/F, F/M, F/F based on donor/recipient sex. I Stratification for multivariable analysis for Chronic GvHD (MRD): for year of HSCT -2000 HSCT - -2004 HSCT - , 2005 HSCT - -2008 HSCT - , and 2009 HSCT - -2012  for graft source -bone marrow and peripheral blood; for conditioning regimen -cyclophosphamide + TBI +/-others, TBI+/others, busulfan + cyclophosphamide +/-others, busulfan + fludarabine, and others. j Stratification for multivariable analysis for Chronic GvHD (MUD): for graft source -bone marrow and peripheral blood; for disease type -AML, MDS, CML and ALL; for conditioning regimen -cyclophosphamide + TBI +/-others, TBI+/-others, busulfan + cyclophosphamide +/-others, busulfan + fludarabine, and others; for recipient age -18-29, 30-39, 40-,49 and 50+; for GVHD ppx -MMF, not MMF. Ppx -prophylaxis Bold values indicate significance at p-value <0.01. Italicized values indicate 0.1< p-value <0.05.
Supplemental Table 3. Demographics of subgroups without or with UGI symptoms within each stage of acute GvHD
Characteristics of patients: Table 2 and Primary Manuscript Tables 3A, 3B , and 4 were derived from the same multivariable treating time of transplantation as the starting point and involving all patient GvHD-related groupings, although only particular comparisons are cited in each tableIn this analysis, patients with isolated UGI GvHD were set as the baseline comparator (HR =1.0).
Supplemental Figure Legends
Supplemental Figure 1 . Subgroups of subjects with acute GvHD analyzed. Top row: Pairwise comparisons were performed between clinical outcomes in subjects with isolated upper GI acute GvHD (iUGI aGvHD) and patients with Grade I, Grade II, or Grades III/IV aGvHD without UGI manifestations as demonstrated by arrows, with arrow heads in the respective subsets being compared. Bottom row: Pairwise comparisons between subjects with aGvHD involving various organs without any UGI involvement and those with similar organ involvement with concomitant UGI involvement were performed as demonstrated by arrows, with arrow heads in the respective subsets being compared. To accomplish this, subjects with Grade II aGvHD were separated into 4 categories: iUGI, Stage 1/2 Skin plus UGI disease; and Hepatic/Lower GI Stage 1 and/or Skin Stage 3 disease, either with or without UGI involvement.
Supplemental Figure 1. Subgroups of subjects with acute GvHD analyzed
Numerals indicate organ-specific stage
